What is FluGen?
FluGen Inc. is a clinical-stage biotechnology company dedicated to the development of next-generation vaccines. Its core innovation, the M2SR Vaccine Platform, represents a significant departure from traditional inactivated flu shots. By utilizing a live, single-replication virus, the M2SR candidate is engineered to stimulate a comprehensive immune response, offering superior protection against both seasonal and drifted influenza strains. Beyond its primary focus on influenza, the company is actively exploring the versatility of the M2SR platform to address other respiratory illnesses, including potential applications for COVID-19. This strategic pivot toward a broader respiratory portfolio positions FluGen as a key player in the evolving landscape of infectious disease prevention.
How much funding has FluGen raised?
FluGen has raised a total of $20.4M across 5 funding rounds:
Debt
$3.2M
Other Financing Round
$9.4M
Series A
$2M
Debt
$5.5M
Debt
$234K
Debt (2014): $3.2M, investors not publicly disclosed
Other Financing Round (2015): $9.4M led by Venture Investors, State of Wisconsin - Investment Board, Knox Payments, and Wisconsin Alumni Research Foundation
Series A (2017): $2M supported by Knox Payments, Venture Investors, Wisconsin Alumni Research Foundation, and State of Wisconsin - Investment Board
Debt (2017): $5.5M, investors not publicly disclosed
Debt (2021): $234K backed by PPP
Key Investors in FluGen
Venture Investors
A venture capital firm specializing in early-stage healthcare and life sciences, focusing on transformative innovations that emerge from world-class research universities.
Wisconsin Alumni Research Foundation
An independent, nonprofit foundation that manages intellectual property and investment portfolios to support scientific research and innovation at the University of Wisconsin-Madison.
State of Wisconsin - Investment Board
A state-owned investment manager that oversees public retirement funds and trust assets, employing fundamental research and tactical asset allocation across global markets.
What's next for FluGen?
Looking ahead, FluGen is poised to transition its M2SR platform through critical phases of clinical development. The recent strategic investment provides the necessary runway to expand trial operations and refine manufacturing processes for its intranasal vaccine candidates. As the company moves forward, the focus will likely remain on demonstrating the platform's efficacy in diverse patient demographics and securing regulatory milestones. By maintaining its commitment to rigorous scientific investigation and leveraging its strong institutional backing, FluGen is strategically aligned to capture significant market share in the global vaccine sector, potentially setting a new benchmark for respiratory disease mitigation.
See full FluGen company page
